Agenus Inc. They have a strong focus on immunotherapy, which involves creating drugs that empower the immune system to effectively combat disease. Their flagship product, Botensilimab, is a next-generation CTLA-4 antibody designed to extend the curative benefits of immunotherapy to cold tumors that do not respond to approved treatments.

It also aims to expand clinical benefit in hot tumors like melanoma, where current treatments show limited success. One of the unique features of Botensilimab is its improved tolerability, reducing or eliminating side effects that often lead to treatment discontinuation. Agenus has a diverse portfolio of immunotherapies and is vertically integrated, covering the entire process from discovery to manufacturing.

They also collaborate with industry leaders to accelerate the development of their programs. With a dedicated team of over 400 employees, Agenus is committed to advancing their mission and providing innovative solutions in the fight against cancer